EZH2 and small cell lung carcinoma: Notably, high expression of EZH2, the catalytic component of PRC2, is a typical feature of both SCLC and neuroblastoma (Figures S1F and S1G), and has been implicated in pathogenesis and therapy resistance (Gardner et al., 2017, Chen et al., 2018).